| Code | CSB-RA011664MB7HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to olokizumab, targeting interleukin-6 (IL-6), a pleiotropic cytokine that plays a central role in immune regulation and inflammatory responses. IL-6 mediates its effects through both classical and trans-signaling pathways, influencing acute phase reactions, B-cell differentiation, T-cell activation, and hematopoiesis. Dysregulated IL-6 production is implicated in numerous pathological conditions, including rheumatoid arthritis, cytokine release syndrome, inflammatory bowel disease, and various autoimmune disorders, making it a critical therapeutic target for inflammatory diseases.
Olokizumab is a humanized IgG4 monoclonal antibody that binds to a unique epitope on IL-6, specifically blocking its interaction with the IL-6 receptor while preserving the cytokine's structural integrity. This biosimilar provides researchers with a valuable tool for investigating IL-6-mediated signaling pathways, exploring cytokine biology in inflammatory disease models, and evaluating potential therapeutic interventions. The antibody supports studies examining immune cell function, inflammatory cascade mechanisms, and the role of IL-6 in both physiological and pathological processes.
There are currently no reviews for this product.